RU2342365C2 - Арилзамещенные пиразоламиды в качестве ингибиторов киназ - Google Patents
Арилзамещенные пиразоламиды в качестве ингибиторов киназ Download PDFInfo
- Publication number
- RU2342365C2 RU2342365C2 RU2005135162/04A RU2005135162A RU2342365C2 RU 2342365 C2 RU2342365 C2 RU 2342365C2 RU 2005135162/04 A RU2005135162/04 A RU 2005135162/04A RU 2005135162 A RU2005135162 A RU 2005135162A RU 2342365 C2 RU2342365 C2 RU 2342365C2
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- halogen
- pyridyl
- bond
- compound according
- Prior art date
Links
- BNYCHCAYYYRJSH-UHFFFAOYSA-N 1h-pyrazole-5-carboxamide Chemical class NC(=O)C1=CC=NN1 BNYCHCAYYYRJSH-UHFFFAOYSA-N 0.000 title claims 2
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 8
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 7
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims abstract 3
- 229910052799 carbon Inorganic materials 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims abstract 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims abstract 2
- 125000001424 substituent group Chemical group 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 33
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- -1 N-morpholinyl Chemical group 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 238000002483 medication Methods 0.000 abstract 3
- 125000003277 amino group Chemical group 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46702903P | 2003-05-01 | 2003-05-01 | |
| US60/467,029 | 2003-05-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005135162A RU2005135162A (ru) | 2006-05-10 |
| RU2342365C2 true RU2342365C2 (ru) | 2008-12-27 |
Family
ID=33435012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005135162/04A RU2342365C2 (ru) | 2003-05-01 | 2004-05-03 | Арилзамещенные пиразоламиды в качестве ингибиторов киназ |
Country Status (27)
| Country | Link |
|---|---|
| US (8) | US7414056B2 (OSRAM) |
| EP (5) | EP2133348B1 (OSRAM) |
| JP (1) | JP4601611B2 (OSRAM) |
| KR (1) | KR20060022649A (OSRAM) |
| CN (1) | CN1816529A (OSRAM) |
| AT (2) | ATE482200T1 (OSRAM) |
| AU (1) | AU2004236240C1 (OSRAM) |
| BR (1) | BRPI0409949A (OSRAM) |
| CA (1) | CA2524321A1 (OSRAM) |
| CO (1) | CO5640039A2 (OSRAM) |
| DE (1) | DE602004029242D1 (OSRAM) |
| DK (1) | DK1618092T3 (OSRAM) |
| ES (3) | ES2386784T3 (OSRAM) |
| GE (1) | GEP20074236B (OSRAM) |
| HR (1) | HRP20100670T1 (OSRAM) |
| IS (1) | IS8101A (OSRAM) |
| MX (1) | MXPA05011666A (OSRAM) |
| NO (1) | NO20054970L (OSRAM) |
| NZ (1) | NZ543375A (OSRAM) |
| PL (1) | PL1618092T3 (OSRAM) |
| PT (1) | PT1618092E (OSRAM) |
| RS (1) | RS20050789A (OSRAM) |
| RU (1) | RU2342365C2 (OSRAM) |
| SI (1) | SI1618092T1 (OSRAM) |
| UA (1) | UA81668C2 (OSRAM) |
| WO (3) | WO2004098518A2 (OSRAM) |
| ZA (1) | ZA200508830B (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2583158C2 (ru) * | 2014-06-06 | 2016-05-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" | Метил 5-(арилкарбамоил)-1-(бензил и фенил)-4-циннамоил-1н-пиразол-3-карбоксилаты, проявляющие анальгетическую активность, и способ их получения |
Families Citing this family (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859031A (en) * | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
| US7078419B2 (en) * | 2003-03-10 | 2006-07-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
| WO2004098518A2 (en) | 2003-05-01 | 2004-11-18 | Bristol-Myers Squibb Company | Pyrazole-amide compounds useful as kinase inhibitors |
| BRPI0412259B1 (pt) | 2003-07-22 | 2019-08-20 | Astex Therapeutics Limited | Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica |
| CA2547410C (en) * | 2003-12-03 | 2013-07-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,2,3-triazole amide derivatives as inhibitors of cytokie production |
| EP1694686A1 (en) | 2003-12-19 | 2006-08-30 | Takeda San Diego, Inc. | Kinase inhibitors |
| PL1725544T3 (pl) * | 2004-03-09 | 2009-10-30 | Boehringer Ingelheim Pharmaceuticals Inc | 3-[4-Heterocyklilo-1,2,3-triazol-1-ilo]-N-arylobenzamidy jako inhibitory wytwarzania cytokin, do leczenia przewlekłych chorób zapalnych |
| WO2005105788A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
| JP4865702B2 (ja) * | 2004-05-03 | 2012-02-01 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン阻害剤 |
| US7485657B2 (en) * | 2004-05-12 | 2009-02-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-cytokine heterocyclic compounds |
| EP1778669A2 (en) | 2004-08-18 | 2007-05-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| MX2007004403A (es) | 2004-10-12 | 2007-04-27 | Astrazeneca Ab | Derivados de quinazolina. |
| ATE479687T1 (de) * | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
| US7531560B2 (en) * | 2004-11-10 | 2009-05-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-cytokine heterocyclic compounds |
| RU2425677C2 (ru) * | 2005-01-21 | 2011-08-10 | Астекс Терапьютикс Лимитед | Соединения, предназначенные для использования в фармацевтике |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| WO2006137376A1 (ja) | 2005-06-21 | 2006-12-28 | Mitsui Chemicals, Inc. | アミド誘導体ならびに該化合物を含有する殺虫剤 |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| WO2007052843A1 (ja) * | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| AU2006328186A1 (en) * | 2005-12-22 | 2007-06-28 | Astrazeneca Ab | Chemical compounds |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| BRPI0708974A2 (pt) | 2006-03-22 | 2011-06-21 | Hoffmann La Roche | composto, composição farmacêutica, métodos de tratamento de diabetes, obesidade ou sìndrome metabólica e uso do composto |
| JP2010505961A (ja) * | 2006-10-09 | 2010-02-25 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| EP2079728B1 (en) | 2006-10-10 | 2013-09-25 | Amgen Inc. | N-aryl pyrazole compounds for use against diabetes |
| CN101616667A (zh) * | 2006-10-27 | 2009-12-30 | 百时美施贵宝公司 | 可用作激酶抑制剂的杂环酰胺化合物 |
| EP2079702A1 (en) * | 2006-10-30 | 2009-07-22 | Novartis AG | 3-amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases |
| US20100004293A1 (en) * | 2006-12-20 | 2010-01-07 | Bristol-Myers Squibb Company | Crystalline forms of aryl-substituted pyrazole-amide compounds |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| ES2340640T3 (es) | 2007-03-23 | 2010-06-07 | Icagen, Inc. | Inhibidores de canales de iones. |
| JP2010522770A (ja) * | 2007-03-29 | 2010-07-08 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ａｋｔ活性の阻害物質 |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| AU2008257559B2 (en) | 2007-05-25 | 2013-10-10 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (MGLU2 receptor) |
| JP5189165B2 (ja) | 2007-07-17 | 2013-04-24 | エフ．ホフマン−ラ ロシュ アーゲー | １１β−ヒドロキシステロイドデヒドロゲナーゼの阻害剤 |
| AU2008279447A1 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
| ES2442926T3 (es) | 2007-08-22 | 2014-02-14 | Astrazeneca Ab | Derivados de ciclopropilamida `978 |
| US8080546B2 (en) | 2007-10-26 | 2011-12-20 | Amgen Inc. | Pyrazolo-pyridinone derivatives and methods of use |
| WO2009057784A1 (ja) | 2007-11-01 | 2009-05-07 | Takeda Pharmaceutical Company Limited | 複素環化合物 |
| KR101616140B1 (ko) * | 2008-03-05 | 2016-04-27 | 다케다 야쿠힌 고교 가부시키가이샤 | 복소환 화합물 |
| JP2011520897A (ja) | 2008-05-16 | 2011-07-21 | シェーリング コーポレイション | グルカゴン受容体アンタゴニスト、組成物およびそれらの使用方法 |
| EP2151434A1 (en) | 2008-08-05 | 2010-02-10 | Institut Pasteur | Alkoxypyrazoles and the process for their preparation |
| CN102186809A (zh) | 2008-08-14 | 2011-09-14 | 拜尔农作物科学股份公司 | 杀虫性的4-苯基-1h-吡唑 |
| EP2184273A1 (de) * | 2008-11-05 | 2010-05-12 | Bayer CropScience AG | Halogen-substituierte Verbindungen als Pestizide |
| WO2010071583A1 (en) * | 2008-12-18 | 2010-06-24 | Astrazeneca Ab | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient |
| PE20100443A1 (es) * | 2009-02-06 | 2010-06-25 | Takeda Pharmaceutical | Derivados del acido fenil-carbonil-amino-propanoico como antagonistas del glucagon |
| TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| WO2011041154A1 (en) | 2009-10-01 | 2011-04-07 | Metabolex, Inc. | Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts |
| NZ602110A (en) | 2010-02-18 | 2014-09-26 | Astrazeneca Ab | Processes for making cyclopropyl amide derivatives and intermediates associated therewith |
| CN110269856A (zh) | 2010-03-30 | 2019-09-24 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
| CN102933572B (zh) | 2010-04-07 | 2015-01-07 | 霍夫曼-拉罗奇有限公司 | 吡唑-4-基-杂环基-甲酰胺化合物及其使用方法 |
| CA2799154A1 (en) | 2010-05-12 | 2011-11-17 | Abbvie Inc. | Indazole inhibitors of kinase |
| WO2012138809A1 (en) * | 2011-04-05 | 2012-10-11 | Dawei Zhang | Heterocyclic compounds as kinase inhibitors |
| JP6299591B2 (ja) * | 2012-07-03 | 2018-03-28 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
| ES2707323T3 (es) | 2012-12-07 | 2019-04-03 | Chemocentryx Inc | Diazol lactamas |
| US20140179712A1 (en) | 2012-12-21 | 2014-06-26 | Astrazeneca Ab | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide |
| ES2648994T3 (es) | 2012-12-21 | 2018-01-09 | Chemocentryx, Inc. | Diazolamidas como antagonistas del receptor CCR1 |
| KR20150130405A (ko) * | 2013-03-15 | 2015-11-23 | 베르선 코포레이션 | 트롬빈의 억제제로서의 할로게노피라졸 |
| RU2678830C2 (ru) | 2013-03-15 | 2019-02-04 | Версеон Корпорейшн | Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз |
| PE20161035A1 (es) | 2013-03-15 | 2016-11-13 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| US20160304466A1 (en) * | 2013-12-04 | 2016-10-20 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
| JP2017505337A (ja) | 2014-01-10 | 2017-02-16 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Ｉｒａｋ４阻害剤としてのインダゾール化合物 |
| PL3805233T3 (pl) | 2014-01-13 | 2024-06-10 | Aurigene Oncology Limited | ENANCJOMERY (R) I (S) (S)-N-(5-(3-hydroksypirolidyn-1-ylo)-2-morfolinooksazolo[4,5-b]pirydyn-6-ylo)-2-(2-metylopirydyn-4-ylo)oksazolo-4-karboksyamidu jako inhibitory IRAK4 do leczenia nowotworu złośliwego |
| WO2015143652A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| WO2015143654A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| WO2015143653A1 (en) | 2014-03-26 | 2015-10-01 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| US9815792B2 (en) | 2014-04-02 | 2017-11-14 | Bayer Cropscience Aktiengesellschaft | Method for producing carboxamides |
| EP3140298A1 (en) | 2014-05-07 | 2017-03-15 | Pfizer Inc. | Tropomyosin-related kinase inhibitors |
| US10356904B2 (en) * | 2014-05-14 | 2019-07-16 | AT&S Austria Technologie & Systemtechnik Aktiengesellshaft | Conductor track with enlargement-free transition between conductor path and contact structure |
| CN106456609A (zh) * | 2014-06-20 | 2017-02-22 | 奥瑞基尼探索技术有限公司 | 作为irak4抑制剂的取代的吲唑化合物 |
| JP2017528486A (ja) | 2014-09-17 | 2017-09-28 | ヴァーセオン コーポレイション | セリンプロテアーゼ阻害剤としてのピラゾリル置換ピリドン化合物 |
| HK1246164A1 (zh) | 2015-02-27 | 2018-09-07 | Verseon Corporation | 作为丝氨酸蛋白酶抑制剂的被取代的吡唑化合物 |
| WO2016161572A1 (en) | 2015-04-08 | 2016-10-13 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| WO2016202935A1 (en) | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| PL3395801T3 (pl) * | 2015-12-16 | 2021-10-18 | Nippon Soda Co., Ltd. | Związek aryloazolowy i środek do zwalczania szkodników |
| WO2017176965A1 (en) | 2016-04-07 | 2017-10-12 | Chemocentryx, Inc. | Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors |
| CA3032432A1 (en) | 2016-08-03 | 2018-02-08 | Charles A. Mcwherter | Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions |
| EP3512833B1 (en) | 2016-09-15 | 2020-07-29 | Boehringer Ingelheim International GmbH | Heteroaryl carboxamide compounds as inhibitors of ripk2 |
| US10414753B2 (en) * | 2016-10-26 | 2019-09-17 | Rigel Pharmaceuticals, Inc. | Amide compounds and method for making and using |
| KR102530512B1 (ko) * | 2016-11-03 | 2023-05-08 | 브리스톨-마이어스 스큅 컴퍼니 | Romk 채널 억제제로서 유용한 치환된 비사이클 헤테로시클릭 유도체 |
| TWI795381B (zh) * | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| CN120267671A (zh) | 2017-03-31 | 2025-07-08 | 奥锐金肿瘤有限公司 | 用于治疗血液病的化合物和组合物 |
| EP3692144A1 (en) | 2017-10-05 | 2020-08-12 | Fulcrum Therapeutics, Inc. | Use of p38 inhibitors to reduce expression of dux4 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| JP7241747B2 (ja) | 2017-10-31 | 2023-03-17 | キュリス，インコーポレイテッド | 血液学的障害を治療するための化合物および組成物 |
| CN110028450A (zh) * | 2018-01-12 | 2019-07-19 | 沈阳中化农药化工研发有限公司 | 一种吡唑酰胺类化合物的制备方法 |
| US10829485B2 (en) | 2018-04-06 | 2020-11-10 | Black Belt Tx Ltd | ATF6 inhibitors and uses thereof |
| KR20210024002A (ko) | 2018-06-18 | 2021-03-04 | 얀센 파마슈티카 엔.브이. | Malt1 억제제로서의 피라졸 유도체 |
| MX2020013899A (es) | 2018-06-18 | 2021-05-27 | Janssen Pharmaceutica Nv | Derivados de pirazol como inhibidores de malt1. |
| US20210236466A1 (en) * | 2018-07-03 | 2021-08-05 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| BR112021019799A2 (pt) | 2019-04-11 | 2021-12-07 | Janssen Pharmaceutica Nv | Derivados contendo anéis de piridina como inibidores de malt1 |
| US11427558B1 (en) | 2019-07-11 | 2022-08-30 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
| CN117120054A (zh) | 2021-04-08 | 2023-11-24 | 柯里斯公司 | 治疗癌症的组合疗法 |
| WO2024226603A1 (en) * | 2023-04-24 | 2024-10-31 | Regents Of The University Of Minnesota | Therapeutic compounds |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002088090A2 (en) * | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Pyrazole derived kinase inhibitors |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4134987A (en) * | 1976-01-14 | 1979-01-16 | Huppatz John L | Compounds and compositions |
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| JPH04316559A (ja) | 1990-11-28 | 1992-11-06 | Nissan Chem Ind Ltd | ピラゾールカルボキサニリド誘導体及び殺菌剤 |
| GB9816837D0 (en) | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
| KR100214732B1 (ko) | 1992-12-14 | 1999-08-02 | 세야 히로미치 | 유리제품의 성형 방법 및 장치 |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| US6020357A (en) | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| AUPO622597A0 (en) * | 1997-04-15 | 1997-05-08 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| US5998424A (en) | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| ES2188005T3 (es) | 1997-09-23 | 2003-06-16 | Astrazeneca Ab | Derivados de amidas para el tratamiento de enfermedades mediadas por citoquinas. |
| US6316466B1 (en) * | 1998-05-05 | 2001-11-13 | Syntex (U.S.A.) Llc | Pyrazole derivatives P-38 MAP kinase inhibitors |
| CA2331878A1 (en) | 1998-05-14 | 1999-11-18 | G.D. Searle & Co. | 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors |
| US6200968B1 (en) | 1998-08-06 | 2001-03-13 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
| EP1115707B1 (en) * | 1998-09-25 | 2003-11-12 | AstraZeneca AB | Benzamide derivatives and ther use as cytokine inhibitors |
| CZ20011965A3 (cs) | 1998-12-04 | 2001-09-12 | Bristol-Myers Squibb Company | Derivát v poloze 3 substituovaného 4-arylchinolin-2-onu jako modulátor draslíkového kanálku |
| DE60017115T2 (de) * | 1999-02-10 | 2005-12-08 | Mitsubishi Pharma Corp. | Amid-derivate und deren medizinische verwendung |
| US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
| DE60020560T2 (de) | 1999-06-03 | 2006-04-27 | Teikoku Hormone Mfg. Co., Ltd. | Substituierte pyrazol-derivate |
| FR2795726A1 (fr) * | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
| DE60033684T2 (de) | 1999-11-18 | 2007-12-06 | Ajinomoto Co., Inc. | Phenylalaninderivate |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| US6569885B1 (en) | 1999-12-23 | 2003-05-27 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| US6194132B1 (en) * | 1999-12-28 | 2001-02-27 | Eastman Kodak Company | Photographic element, compound, and process |
| US6197492B1 (en) * | 1999-12-28 | 2001-03-06 | Eastman Kodak Company | Photographic element, compound, and process |
| US20020065270A1 (en) | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| US6906067B2 (en) | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| MY138097A (en) | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
| IL153645A0 (en) * | 2000-07-31 | 2003-07-06 | Smithkline Beecham Plc | Carboxamide compounds and their use as antagonists of a human 11cby receptor |
| WO2002023986A1 (en) * | 2000-08-25 | 2002-03-28 | Sankyo Company, Limited | 4-acylaminopyrazole derivatives |
| HU228960B1 (hu) | 2000-10-30 | 2013-07-29 | Kudos Pharm Ltd | Ftalazinon-származékok |
| GB0102687D0 (en) | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
| CA2446756C (en) | 2001-06-01 | 2011-03-08 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinase |
| EP1406875B1 (en) | 2001-06-26 | 2013-07-31 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of tnf-alpha expression |
| EP1451160B1 (en) * | 2001-11-01 | 2010-01-13 | Icagen, Inc. | Pyrazole-amides for use in the treatment of pain |
| WO2003050261A2 (en) | 2001-12-10 | 2003-06-19 | Bristol-Myers Squibb Company | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase |
| US6521395B1 (en) * | 2002-01-30 | 2003-02-18 | Eastman Kodak Company | Infrared couplers for incorporating and recovering metadata |
| WO2003064389A1 (en) | 2002-01-31 | 2003-08-07 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient |
| DE60329513D1 (de) * | 2002-07-30 | 2009-11-12 | Banyu Pharma Co Ltd | Antagonist des melanin-concentrating-hormone-rezeptors, enthaltend ein benzimidazolderivat als wirkstoff |
| EP1546089A2 (en) | 2002-08-09 | 2005-06-29 | TransTech Pharma Inc. | Aryl and heteroaryl compounds and methods to modulate coagulation |
| WO2004035545A2 (en) | 2002-10-18 | 2004-04-29 | E.I. Du Pont De Nemours And Company | Azolecarboxamide herbicides |
| AU2003296404A1 (en) * | 2003-01-06 | 2004-08-10 | Eli Lilly And Company | Heterocyclic ppar modulators |
| DE602004028907D1 (de) | 2003-02-06 | 2010-10-14 | Bristol Myers Squibb Co | Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis |
| WO2004098518A2 (en) * | 2003-05-01 | 2004-11-18 | Bristol-Myers Squibb Company | Pyrazole-amide compounds useful as kinase inhibitors |
| WO2004106324A1 (en) | 2003-05-27 | 2004-12-09 | E.I. Dupont De Nemours And Company | Azolecarboxamide herbicides |
| US7419978B2 (en) | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
| GB0329572D0 (en) | 2003-12-20 | 2004-01-28 | Astrazeneca Ab | Amide derivatives |
| US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| US7652146B2 (en) | 2004-02-06 | 2010-01-26 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors |
| TWI338004B (en) | 2004-02-06 | 2011-03-01 | Bristol Myers Squibb Co | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| US20060069132A1 (en) | 2004-04-07 | 2006-03-30 | Armel Gregory R | Azolecarboxamide herbicides |
| US20080312215A1 (en) | 2005-06-28 | 2008-12-18 | Pharmacopeia Drug Discovery, Inc. | Substituted [1,4]-diazepanes as CXCR3 antagonists and their use in the treatment of inflammatory disorders |
-
2004
- 2004-05-03 WO PCT/US2004/013594 patent/WO2004098518A2/en not_active Ceased
- 2004-05-03 BR BRPI0409949-4A patent/BRPI0409949A/pt not_active IP Right Cessation
- 2004-05-03 UA UAA200511373A patent/UA81668C2/ru unknown
- 2004-05-03 EP EP09010209A patent/EP2133348B1/en not_active Expired - Lifetime
- 2004-05-03 SI SI200431517T patent/SI1618092T1/sl unknown
- 2004-05-03 EP EP11005867.4A patent/EP2385041B1/en not_active Expired - Lifetime
- 2004-05-03 ES ES04760705T patent/ES2386784T3/es not_active Expired - Lifetime
- 2004-05-03 US US10/837,778 patent/US7414056B2/en not_active Expired - Lifetime
- 2004-05-03 EP EP04760705A patent/EP1620108B1/en not_active Expired - Lifetime
- 2004-05-03 US US10/838,006 patent/US7151113B2/en not_active Expired - Lifetime
- 2004-05-03 JP JP2006514216A patent/JP4601611B2/ja not_active Expired - Fee Related
- 2004-05-03 CN CNA2004800188458A patent/CN1816529A/zh active Pending
- 2004-05-03 PL PL04751133T patent/PL1618092T3/pl unknown
- 2004-05-03 AU AU2004236240A patent/AU2004236240C1/en not_active Ceased
- 2004-05-03 ES ES04751133T patent/ES2350837T3/es not_active Expired - Lifetime
- 2004-05-03 EP EP04751133A patent/EP1618092B1/en not_active Expired - Lifetime
- 2004-05-03 AT AT04751133T patent/ATE482200T1/de active
- 2004-05-03 GE GEAP20049086A patent/GEP20074236B/en unknown
- 2004-05-03 HR HR20100670T patent/HRP20100670T1/hr unknown
- 2004-05-03 ES ES09010209T patent/ES2370463T3/es not_active Expired - Lifetime
- 2004-05-03 EP EP04760683A patent/EP1617840A4/en not_active Withdrawn
- 2004-05-03 US US10/838,129 patent/US7396935B2/en not_active Expired - Lifetime
- 2004-05-03 PT PT04751133T patent/PT1618092E/pt unknown
- 2004-05-03 NZ NZ543375A patent/NZ543375A/en unknown
- 2004-05-03 KR KR1020057020642A patent/KR20060022649A/ko not_active Ceased
- 2004-05-03 CA CA002524321A patent/CA2524321A1/en not_active Abandoned
- 2004-05-03 RS YUP-2005/0789A patent/RS20050789A/sr unknown
- 2004-05-03 RU RU2005135162/04A patent/RU2342365C2/ru not_active IP Right Cessation
- 2004-05-03 WO PCT/US2004/013786 patent/WO2004098528A2/en not_active Ceased
- 2004-05-03 DK DK04751133.2T patent/DK1618092T3/da active
- 2004-05-03 DE DE602004029242T patent/DE602004029242D1/de not_active Expired - Lifetime
- 2004-05-03 AT AT09010209T patent/ATE522525T1/de not_active IP Right Cessation
- 2004-05-03 MX MXPA05011666A patent/MXPA05011666A/es active IP Right Grant
- 2004-05-03 WO PCT/US2004/013604 patent/WO2004099156A1/en not_active Ceased
-
2005
- 2005-10-26 NO NO20054970A patent/NO20054970L/no not_active Application Discontinuation
- 2005-10-28 IS IS8101A patent/IS8101A/is unknown
- 2005-10-31 ZA ZA200508830A patent/ZA200508830B/xx unknown
- 2005-11-01 CO CO05111218A patent/CO5640039A2/es not_active Application Discontinuation
-
2006
- 2006-06-28 US US11/477,010 patent/US7253170B2/en not_active Expired - Lifetime
-
2007
- 2007-08-02 US US11/832,924 patent/US7592338B2/en not_active Expired - Lifetime
- 2007-10-31 US US11/931,309 patent/US7390810B2/en not_active Expired - Lifetime
-
2008
- 2008-05-12 US US12/118,794 patent/US7605273B2/en not_active Expired - Lifetime
-
2009
- 2009-09-18 US US12/562,383 patent/US20100016320A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002088090A2 (en) * | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Pyrazole derived kinase inhibitors |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2583158C2 (ru) * | 2014-06-06 | 2016-05-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" | Метил 5-(арилкарбамоил)-1-(бензил и фенил)-4-циннамоил-1н-пиразол-3-карбоксилаты, проявляющие анальгетическую активность, и способ их получения |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2342365C2 (ru) | Арилзамещенные пиразоламиды в качестве ингибиторов киназ | |
| RU2329263C2 (ru) | Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с | |
| RU2328486C2 (ru) | Производные 2-пиридона в качестве ингибиторов нейтрофильной эластазы | |
| RU2497807C2 (ru) | Карбазольные соединения и терапевтические применения соединений | |
| CA2037630A1 (en) | Nitrogen-containing heterocylic compounds, their production and use | |
| WO2003106428A8 (fr) | Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine | |
| MY144655A (en) | Pyrimidine urea derivatives as kinase inhibitors | |
| ATE454152T1 (de) | 2-aminopyrimidin-derivate als raf-kinase-hemmer | |
| DE60235500D1 (de) | Selektive pyrimidin-a2b-antagonistenverbindungen, ihre synthese und verwendung | |
| JP2005535586A5 (OSRAM) | ||
| AU2003273475A8 (en) | N-(phenyl(piperidin-2-yl)methyl)benzamide derivatives, preparation thereof, and use thereof in therapy | |
| AU2001235844A1 (en) | Imidazol-2-carboxamide derivatives as raf kinase inhibitors | |
| JP2010535722A5 (OSRAM) | ||
| DE60103136D1 (de) | Imidazol derivate als raf kinase inhibitoren | |
| CA2539349A1 (en) | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones | |
| JP2004512281A5 (OSRAM) | ||
| JP2001525394A5 (OSRAM) | ||
| WO2005005415A8 (en) | Indoles useful in the treatment of inflammation | |
| ATE480239T1 (de) | Angiogeneseinhibitoren | |
| CA2559128A1 (en) | Kinase inhibitors | |
| JP2003513066A5 (OSRAM) | ||
| EA200500521A1 (ru) | 3-фенилзамещенный пиридоиндолон, его получение и терапевтическое применение | |
| MY143245A (en) | 4- 2-(cycloalkylamino)pyrimidin-4-yl-(phenyl)-imidazolin-2-one derivatives as p38 map-kinase inhibitors for the treatment of inflammatory diseases | |
| DE60213087D1 (de) | Pyrimidin-derivate als selektive inhibitoren von cox-2 | |
| EA200801536A1 (ru) | Новые тиенопирсульфоновые производные |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20070827 |
|
| FZ9A | Application not withdrawn (correction of the notice of withdrawal) |
Effective date: 20071128 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20110504 |